Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-804-2 | CAS number: 12767-90-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 06/03/1990 to 18/04/1990
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Guideline study. Read-across is justified on the following basis: The family of zinc borates that include Zinc Borate 500, Zinc Borate 2335 and Zinc Borate 415 (also known as Zinc Borate 411). Zinc borate 500 is anhydrous Zinc Borate 2335 and Zinc Borate 415 has different zinc to boron ratio. Zinc borate 2335 (in common with other zinc borates such as Zinc borate 415 and 500) breaks down to Zinc Hydroxide (via Zinc oxide) and Boric Acid, therefore the family of zinc borates shares the same toxicological properties. Zinc borates are sparingly soluble salts. Hydrolysis under high dilution conditions leads to zinc hydroxide via zinc oxide and boric acid formation. Zinc hydroxide and zinc oxide solubility is low under neutral and basic conditions. This leads to a situation where zinc borate hydrolyses to zinc hydroxide, zinc oxide and boric acid at neutral pH quicker than it solubilises. Therefore, it can be assumed that at physiological conditions and neutral and lower pH zinc borate will be hydrolysed to boric acid, zinc oxide and zinc hydroxide. Hydrolysis and the rate of hydrolysis depend on the initial loading and time. At a loading of 5% (5g/100ml) zinc borate hydrolysis equilibrium may take 1-2 months, while at 1 g/l hydrolysis is complete after 5 days. At 50 mg/l hydrolysis and solubility is complete (Schubert et al., 2003). At pH 4 hydrolysis is complete. Zinc Borate 2335 breaks down as follows: 2ZnO • 3B2O3 •3.5H2O + 3.5H2O + 4H+ ↔ 6H3BO3 + 2Zn2+ 2Zn2+ + 4OH- ↔ 2Zn(OH)2 ____________________________________________________________ Overall equation 2ZnO • 3B2O3 •3.5H2O + 7.5H2O ↔ 2Zn(OH)2 + 6H3BO3 The relative zinc oxide and boric oxide % are as follows: Zinc borate 2335:zinc oxide = 37.45% (30.09% Zn) B2O3 = 48.05% (14.94% B) Water 14.5% Zinc borate 415: zinc oxide = 78.79%; (63.31% Zn) B2O3 = 16.85% (5.23% B) Water 4.36% Zinc borate, anhydrous: Zinc oxide = 45 % B2O3= 55% (17.1 % B)
- Qualifier:
- according to guideline
- Guideline:
- other: Federal Insecticide, Fungicide and Rodenticide Act (40 CFR)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- other: Toxic Substances Control Act (40 CFR)
- Deviations:
- not specified
- GLP compliance:
- yes
- Type of study:
- Buehler test
- Justification for non-LLNA method:
- OECD Guideline 406 "Skin Sensitisation" method (Buehler test ) was performed before the LLNA was set as preferred test method.
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Murphy Breeding Laboratories, Inc.
- Weight at study initiation: 381 - 538 g
- Housing: Individually in wire mesh suspension cages.
- Diet: Ad libitum
- Water: Ad libitum
- Acclimation period: Animals will be quarantined for at least 4 days.
ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light): 12 h dark/12 h light cycle.
IN-LIFE DATES: From: 12/03/1990 To: 18/04/1990 - Route:
- epicutaneous, occlusive
- Vehicle:
- water
- Concentration / amount:
- 75 % w/v formulation in distilled water.
- Route:
- epicutaneous, occlusive
- Vehicle:
- water
- Concentration / amount:
- 75 % w/v formulation in distilled water.
- No. of animals per dose:
- Pilot studies: Four in each of two pilots
Main study: See table. - Details on study design:
- RANGE FINDING TESTS:
Pilot No. 1: Six h patch test at 5 %, 2.5 %, 1 % and 0.5 % w/v using 2 males and 2 females.
Pilot No. 2: Six h patch test at 75 %, 50 %, 25 % and 10 % w/v using 2 males and 2 females.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: Three
- Exposure period: 6-hours per exposure
- Site: Left shoulder
- Frequency of applications: Once per week
B. CHALLENGE EXPOSURE
- No. of exposures: Single challenge
- Day(s) of challenge: Approximately two weeks after last induction.
- Site: Varied, but on skin that had not previously been previously exposed.
- Concentrations: 75 % w/v
- Evaluation (hr after challenge): 24 and 48 h - Positive control substance(s):
- yes
- Remarks:
- Historical data on DNCB
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 75 % w/v
- No. with + reactions:
- 9
- Total no. in group:
- 20
- Clinical observations:
- Slightly patchy erythema.
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 75 % w/v. No with. + reactions: 9.0. Total no. in groups: 20.0. Clinical observations: Slightly patchy erythema..
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 75 % w/v
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 75 % w/v. No with. + reactions: 7.0. Total no. in groups: 10.0.
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information
- Conclusions:
- The potential for FIREBRAKE® ZB zinc borate 2335 as a 75 % w/v formulation in distilled water to produced delayed contact hypersensitivity in guinea pigs was evaluated using an adaptation of the method of Buehler. Following primary challenge there were no grades of 1 produced in the test or control animals. The incidence of grade ± responses in the test group (9 of 20) was compared to that of the naive control group (7 of 10). The incidence of these responses in the test group was less than that produced by the naive control group indicating that sensitisation had not been induced.
Read-across is justified on the basis detailed in the rationale for reliability above. This study is therefore considered to be of sufficient adequacy and reliability to be used as a key study.
Reference
The incidence and severity of responses were calculated as follows:
Group |
Test materiala |
Concentrationb |
Incidence of responses |
Mean severity scores |
||||||||||
24 h |
48 h |
|||||||||||||
0 |
± |
1 |
2 |
3 |
0 |
± |
1 |
2 |
3 |
24 h |
48 h |
|||
Primary challenge |
||||||||||||||
Test |
TMID |
75 % |
13 |
7 |
0 |
0 |
0 |
15 |
5 |
0 |
0 |
0 |
0.2 |
0.1 |
Naïve control |
TMID |
75 % |
4 |
6 |
0 |
0 |
0 |
3 |
7 |
0 |
0 |
0 |
0.3 |
0.4 |
aTMID- FIREBRAKE®ZB zinc borate 2335
bTest material formulated w/v in distilled water
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Zinc borate was tested in a Buehler method skin sensitisation test (Kreuzmann, 1990) applied at a concentration of 75 % (powder moistened with water) during both the induction and challenge phase of the test. No signs of skin sensitisation were observed.
See toxicokinetic section for read-across justification.
Migrated from Short description of key information:
A skin sensitisation test on zinc borate was performed according to OECD Guideline 406 (Buehler method).
Justification for selection of skin sensitisation endpoint:
Key study conducted with zinc borate heptahydrate.
Respiratory sensitisation
Endpoint conclusion
- Additional information:
- Migrated from Short description of key information:
There are no data to suggest that zinc borate is respiratory sensitiser.
Justification for classification or non-classification
Zinc borate is not a skin or respiratory sensitiser.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
